Loss of tyrosine phosphatase-dependent inhibition promotes activation of tyrosine kinase c-Src in detached pancreatic cells

Molecular Carcinogenesis

Volumn 49, Issue 12, 2010, Pages 1007-1021

  Connelly, Sarah F ^a   Isley, Beth A ^a   Baker, Cheryl H ^a   Gallick, Gary E ^b   Summy, Justin M ^a  

^a M D ANDERSON CANCER CENTER ORLANDO   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anoikis; Carcinoma; Cell stress; Focal adhesion kinase; P130 CAS; Paxillin

Indexed keywords

PROTEIN KINASE B; PROTEIN SH2; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE SHP 2; SCLEROPROTEIN; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; AUTOPHOSPHORYLATION; CANCER CELL; CELL ADHESION; CELL SURVIVAL; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; MOUSE; NONHUMAN; PANCREAS CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STEADY STATE;

ADENOCARCINOMA; ANOIKIS; CELL ADHESION; CELL LINE, TUMOR; CELL SURVIVAL; ENZYME ACTIVATION; EXTRACELLULAR MATRIX PROTEINS; GENE KNOCKDOWN TECHNIQUES; HUMANS; MAP KINASE KINASE 4; PANCREATIC NEOPLASMS; PHOSPHORYLATION; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; PROTEIN TYROSINE PHOSPHATASES; PROTO-ONCOGENE PROTEINS C-AKT; SRC-FAMILY KINASES;

EID: 78649522904     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20684     Document Type: Article

References (60)

1. Saif MW, Karapanagiotou L, Syrigos K. Genetic alterations in pancreatic cancer. World J Gastroenterol 2007; 13: 4423-4430.
2. Mimeault M, Brand RE, Sasson AA, Batra SK. Recent advances on the molecular mechanisms involved in pancreatic cancer progression and therapies. Pancreas 2005; 31: 301-316.
3. MacKenzie MJ. Molecular therapy in pancreatic adenocarcinoma. Lancet Oncol 2004; 5: 541-549.
4. Adrian TE. Inhibition of pancreatic cancer cell growth. Cell Mol Life Sci 2007; 64: 2512-2521.
5. Wolff RA. Chemotherapy for pancreatic cancer: From metastatic disease to adjuvant therapy. Cancer J (Sudbury, Mass) 2007; 13: 175-184.
6. Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 2003; 22: 337-358.
7. Kim LC, Song L, Haura EB. Src kinases as therapeutic targets for cancer. Nat Rev 2009; 6: 587-595.
8. Frame MC. Newest findings on the oldest oncogene; how activated src does it. J Cell Sci 2004; 117: 989-998.
9. Visser CJ, Rijksen G, Woutersen RA, De Weger RA. Increased immunoreactivity and protein tyrosine kinase activity of the protooncogene pp60c-src in preneoplastic lesions in rat pancreas. Lab Invest 1996; 74: 2-11.
10. Lutz MP, Esser IB, Flossmann-Kast BB, et al. Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem Biophys Res Commun 1998; 243: 503-508.
11. Summy JM, Trevino JG, Baker CH, Gallick GE. c-Src regulates constitutive and EGF-mediated VEGF expression in pancreatic tumor cells through activation of phosphatidyl inositol-3 kinase and p38 MAPK. Pancreas 2005; 31: 263-274.
12. Zeng H, Datta K, Neid M, Li J, Parangi S, Mukhopadhyay D. Requirement of different signaling pathways mediated by insulin-like growth factor-I receptor for proliferation, invasion, and VPF/VEGF expression in a pancreatic carcinoma cell line. Biochem Biophys Res Commun 2003; 302: 46-55.
13. Matsushita A, Gotze T, Korc M. Hepatocyte growth factor-mediated cell invasion in pancreatic cancer cells is dependent on neuropilin-1. Cancer Res 2007; 67: 10309-10316.
14. Olszewska-Pazdrak B, Townsend CM, Jr., Hellmich MR. Agonist-independent activation of Src tyrosine kinase by a cholecystokinin-2 (CCK2) receptor splice variant. J Biol Chem 2004; 279: 40400-40404.
15. Ferrand A, Vatinel S, Kowalski-Chauvel A, et al. Mechanism for Src activation by the CCK2 receptor: Patho-physiological functions of this receptor in pancreas. World J Gastroenterol 2006; 12: 4498-4503.
16. Duxbury MS, Ito H, Benoit E, Waseem T, Ashley SW, Whang EE. A novel role for carcinoembryonic antigen-related cell adhesion molecule 6 as a determinant of gemcitabine chemoresistance in pancreatic adenocarcinoma cells. Cancer Res 2004; 64: 3987-3993.
17. Tsuda M, Matozaki T, Fukunaga K, et al. Integrin-mediated tyrosine phosphorylation of SHPS-1 and its association with SHP-2. Roles of Fak and Src family kinases. J Biol Chem 1998; 273: 13223-13229.
18. Desgrosellier JS, Barnes LA, Shields DJ, et al. An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression. Nat Med 2009; 15: 1163-1169.
19. Ricono JM, Huang M, Barnes LA, et al. Specific cross-talk between epidermal growth factor receptor and integrin alphavbeta5 promotes carcinoma cell invasion and metastasis. Cancer Res 2009; 69: 1383-1391.
20. Yezhelyev MV, Koehl G, Guba M, et al. Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice. Clin Cancer Res 2004; 10: 8028-8036.
21. Koenig A, Mueller C, Hasel C, Adler G, Menke A. Collagen type I induces disruption of E-cadherin-mediated cell-cell contacts and promotes proliferation of pancreatic carcinoma cells. Cancer Res 2006; 66: 4662-4671.
22. Ito H, Gardner-Thorpe J, Zinner MJ, Ashley SW, Whang EE. Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness. Surgery 2003; 134: 221-226.
23. Trevino JG, Summy JM, Gray MJ, et al. Expression and activity of SRC regulate interleukin-8 expression in pancreatic adenocarcinoma cells: Implications for angiogenesis. Cancer Res 2005; 65: 7214-7222.
24. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. siRNA directed against c-Src enhances pancreatic adenocarcinoma cell gemcitabine chemosensitivity. J Am Coll Surg 2004; 198: 953-959.
25. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin Cancer Res 2004; 10: 2307-2318.
26. Ischenko I, Camaj P, Seeliger H, et al. Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: An involvement of epidermal growth factor receptor signaling. Oncogene 2008; 27: 7212-7222.
27. Trevino JG, Summy JM, Lesslie DP, et al. Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol 2006; 168: 962-972.
28. Ischenko I, Guba M, Yezhelyev M, et al. Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer. Angiogenesis 2007; 10: 167-182.
29. Rajeshkumar NV, Tan AC, De Oliveira E, et al. Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer. Clin Cancer Res 2009; 15: 4138-4146.
30. Messersmith WA, Rajeshkumar NV, Tan AC, et al. Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts. Mol Cancer Ther 2009; 8: 1484-1493.
31. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1994; 124: 619-626.
32. Windham TC, Parikh NU, Siwak DR, et al. Src activation regulates anoikis in human colon tumor cell lines. Oncogene 2002; 21: 7797-7807.
33. Giannoni E, Fiaschi T, Ramponi G, Chiarugi P. Redox regulation of anoikis resistance of metastatic prostate cancer cells: Key role for Src and EGFR-mediated pro-survival signals. Oncogene 2009; 28: 2074-2086.
34. Wei L, Yang Y, Zhang X, Yu Q. Altered regulation of Src upon cell detachment protects human lung adenocarcinoma cells from anoikis. Oncogene 2004; 23: 9052-9061.
35. Diaz-Montero CM, Wygant JN, McIntyre BW. PI3-K/Akt-mediated anoikis resistance of human osteosarcoma cells requires Src activation. Eur J Cancer 2006; 42: 1491-1500.
36. Bruns CJ, Harbison MT, Kuniyasu H, Eue I, Fidler IJ. In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. Neoplasia (New York, NY) 1999; 1: 50-62.
37. Summy JM, Trevino JG, Lesslie DP, et al. AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes. Mol Cancer Ther 2005; 4: 1900-1911.
38. Mendieta J, Gago F. In silico activation of Src tyrosine kinase reveals the molecular basis for intramolecular autophosphorylation. J Mol Graph Model 2004; 23: 189-198.
39. Roskoski R, Jr. Src protein-tyrosine kinase structure and regulation. Biochem Biophys Res Commun 2004; 324: 1155-1164.
40. Hurley TR, Hyman R, Sefton BM. Differential effects of expression of the CD45 tyrosine protein phosphatase on the tyrosine phosphorylation of the lck, fyn, and c-src tyrosine protein kinases. Mol Cell Biol 1993; 13: 1651-1656.
41. Su J, Muranjan M, Sap J. Receptor protein tyrosine phosphatase alpha activates Src-family kinases and controls integrin-mediated responses in fibroblasts. Curr Biol 1999; 9: 505-511.
42. Doan T, Farmer P, Cooney T, Ali MS. Selective down-regulation of angiotensin II receptor type 1A signaling by protein tyrosine phosphatase SHP-2 in vascular smooth muscle cells. Cell Signal 2004; 16: 301-311.
43. Walter AO, Peng ZY, Cartwright CA. The Shp-2 tyrosine phosphatase activates the Src tyrosine kinase by a non-enzymatic mechanism. Oncogene 1999; 18: 1911-1920.
44. Zhang SQ, Yang W, Kontaridis MI, et al. Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment. Mol Cell 2004; 13: 341-355.
45. Lessard L, Stuible M, Tremblay ML. The two faces of PTP1B in cancer. Biochim Biophys Acta 2010; 1804: 613-619.
46. Chen L, Sung SS, Yip ML, et al. Discovery of a novel shp2 protein tyrosine phosphatase inhibitor. Mol Pharmacol 2006; 70: 562-570.
47. Song M, Park JE, Park SG, et al. NSC-87877, inhibitor of SHP-1/2 PTPs, inhibits dual-specificity phosphatase 26 (DUSP26). Biochem Biophys Res Commun 2009; 381: 491-495.
48. Lu W, Gong D, Bar-Sagi D, Cole PA. Site-specific incorporation of a phosphotyrosine mimetic reveals a role for tyrosine phosphorylation of SHP-2 in cell signaling. Mol Cell 2001; 8: 759-769.
49. Playford MP, Schaller MD. The interplay between Src and integrins in normal and tumor biology. Oncogene 2004; 23: 7928-7946.
50. Brunton VG, MacPherson IR, Frame MC. Cell adhesion receptors, tyrosine kinases and actin modulators: A complex three-way circuitry. Biochim Biophys Acta 2004; 1692: 121-144.
51. Arias-Salgado EG, Lizano S, Sarkar S, Brugge JS, Ginsberg MH, Shattil SJ. Src kinase activation by direct interaction with the integrin beta cytoplasmic domain. Proc Natl Acad Sci USA 2003; 100: 13298-13302.
52. Ishizawar R, Parsons SJ. c-Src and cooperating partners in human cancer. Cancer cell 2004; 6: 209-214.
53. Loza-Coll MA, Perera S, Shi W, Filmus J. A transient increase in the activity of Src-family kinases induced by cell detachment delays anoikis of intestinal epithelial cells. Oncogene 2005; 24: 1727-1737.
54. Hofmann C, Lippert E, Falk W, Scholmerich J, Rogler G, Obermeier F. Primary human colonic epithelial cells are transiently protected from anoikis by a Src-dependent mechanism. Biochem Biophys Res Commun 2009; 390: 908-914.
55. Kmiecik TE, Johnson PJ, Shalloway D. Regulation by the autophosphorylation site in overexpressed pp60c-src. Mol Cell Biol 1988; 8: 4541-4546.
56. Merritt R, Hayman MJ, Agazie YM. Mutation of Thr466 in SHP2 abolishes its phosphatase activity, but provides a new substrate-trapping mutant. Biochim Biophys Acta 2006; 1763: 45-56.
57. Meng TC, Fukada T, Tonks NK. Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. Mol Cell 2002; 9: 387-399.
58. Chen CH, Cheng TH, Lin H, et al. Reactive oxygen species generation is involved in epidermal growth factor receptor transactivation through the transient oxidization of Src homology 2-containing tyrosine phosphatase in endothelin-1 signaling pathway in rat cardiac fibroblasts. Mol Pharmacol 2006; 69: 1347-1355.
59. Vivas-Mejia P, Benito JM, Fernandez A, et al. c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer. Clin Cancer Res 2009; 16: 184-194.
60. Kennedy NJ, Davis RJ. Role of JNK in tumor development. Cell Cycle (Georgetown, Tex) 2003; 2: 199-201.